Drugs / GSK1043702
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00950586 | Aug → Dec 2009 | cognitive disorder | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK1043702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00950586 ↗ |
| Route | Oral | “Oral dose in liquid or tablet formulation” NCT00950586 ↗ |